Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-10-11
2005-10-11
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S007200, C536S007300
Reexamination Certificate
active
06953782
ABSTRACT:
The present invention discloses compounds of formulae I, II, III or IV or pharmaceutically acceptable salts, esters, or prodrugs thereof:which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
REFERENCES:
patent: 3660376 (1972-05-01), Massey et al.
patent: 4847242 (1989-07-01), Davies
patent: 4990602 (1991-02-01), Morimoto et al.
patent: 5403923 (1995-04-01), Kashimura et al.
patent: 5444051 (1995-08-01), Agouridas et al.
patent: 6395710 (2002-05-01), Chu et al.
patent: 2003/0125266 (2003-07-01), Chu et al.
patent: 2004/0002464 (2004-01-01), Phan et al.
patent: 2004/0006027 (2004-01-01), Phan et al.
patent: WO 98/30574 (1998-07-01), None
patent: WO 03/004509 (2003-01-01), None
patent: WO 03/047600 (2003-06-01), None
Farmer Jay Judson
Or Yat Sun
Phan Ly Tam
Elmore Carolyn S.
Elmore, Craig & Vanstone, P.C.
Enanta Pharmaceuticals, Inc.
Peselev Elli
Vanstone Darlene A.
LandOfFree
11-C-substituted erythromycin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 11-C-substituted erythromycin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 11-C-substituted erythromycin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3456544